2024
Disorders due to Substance Use: General Approaches
Kosten T, Domingo C. Disorders due to Substance Use: General Approaches. 2024, 2527-2542. DOI: 10.1007/978-3-030-51366-5_92.Peer-Reviewed Original ResearchSubstance use disordersDSM-5ICD-11Depressive symptomsSubstance use disorder criteriaBorderline personality disorderSubstance-induced conditionsGoal of abstinenceDrug withdrawal symptomsPersonality disorderDepressive disorderAgonist maintenanceWithdrawal symptomsAcute detoxificationLifetime substanceSUD diagnosisAbused drugsDevelopmental differencesUrine toxicologySubstance useAlcohol usePsychosocial rehabilitationDisordersDrug useSymptomsDexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study
Petrakis I, Nolen T, Vandergrift N, Hirsch S, Krystal J, De Vivo M, Sabados J, Pisani E, Newcomb J, Kosten T. Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study. American Journal On Addictions 2024 PMID: 39152094, DOI: 10.1111/ajad.13637.Peer-Reviewed Original ResearchPathophysiology of posttraumatic stress disorderAlcohol use disorderSubjective effects of alcoholEffects of alcoholUse disorderComorbid alcohol use disorderAlcohol cue reactivityPosttraumatic stress disorderCrossover laboratory studyCue reactivityAlcohol cravingNoradrenergic dysregulationStress disorderBlood pressureSubjective effectsEthanol administrationClinically significant adverse effectsPharmacotherapeutic approachesTest daysReceptor agonistsPotential treatmentDouble-blind fashionCravingDrinking alcoholDisordersUse of Cigarettes and E-Cigarettes, Impulsivity, and Anxiety: Influences on Suicidal Ideation Among Youth and Young Adults in Texas
Wilkinson A, Chen B, Swann A, Graham D, Nielsen D, Kosten T, Loukas A, Mantey D, Bataineh B, Harrell M. Use of Cigarettes and E-Cigarettes, Impulsivity, and Anxiety: Influences on Suicidal Ideation Among Youth and Young Adults in Texas. Nicotine & Tobacco Research 2024, ntae163. PMID: 39028574, DOI: 10.1093/ntr/ntae163.Peer-Reviewed Original ResearchE-cigarette useCigarette useE-cigarettesRisk of suicidal ideationHigh riskCigarette/e-cigarette useTexas Adolescent TobaccoAssociated with higher riskYoung adultsUse of cigarettesSuicidal ideationMixed-effects logistic regressionIncreased risk of suicidal ideationIncreased riskHigher risk of suicidal ideationAdolescent tobaccoInfluence of cigaretteLevels of SESLogistic regressionCigaretteCessation programsTwo-weekMultiple social identitiesRiskAppropriate supportLithium reduces impulsive decision making in transdiagnostic patients at high risk for suicide attempt recurrence: A randomized, double blind, placebo-controlled, crossover study
Murphy N, Pham G, Weyland A, Engelhardt J, Kypriotakis G, Thomas Y, Kosten T, Moukaddam N, Mathew S, Swann A. Lithium reduces impulsive decision making in transdiagnostic patients at high risk for suicide attempt recurrence: A randomized, double blind, placebo-controlled, crossover study. Journal Of Affective Disorders Reports 2024, 17: 100833. DOI: 10.1016/j.jadr.2024.100833.Peer-Reviewed Original ResearchImmediate memory taskInternal State ScaleTime perception tasksSuicidal behaviorImpulsive decisionsSuicide attemptsResponse latencySpectrum of suicidal behaviorsLethal suicidal behaviorMeasures of impulsivityLithium doseConservative response biasSevere suicide attemptsDouble-blind crossover designRandomized double-blind crossover designPrevent suicide riskEffects of lithiumPill placeboMemory taskBehavioral therapySuicide riskResponse biasAdjunctive behavioral therapySelf-harmAssociated with attemptsCognitive enhancing effect of rTMS combined with tDCS in patients with major depressive disorder: a double-blind, randomized, sham-controlled study
Li X, Liu J, Wei S, Yu C, Wang D, Li Y, Li J, Zhuang W, Luo R, Li Y, Liu Z, Su Y, Liu J, Xu Y, Fan J, Zhu G, Xu W, Tang Y, Yan H, Cho R, Kosten T, Zhou D, Zhang X. Cognitive enhancing effect of rTMS combined with tDCS in patients with major depressive disorder: a double-blind, randomized, sham-controlled study. BMC Medicine 2024, 22: 253. PMID: 38902735, PMCID: PMC11188255, DOI: 10.1186/s12916-024-03443-7.Peer-Reviewed Original ResearchConceptsRBANS total scoreRepetitive transcranial magnetic stimulationTranscranial direct current stimulationMDD patientsTotal scoreHDRS-24Transcranial direct current stimulation groupDepressive disorderImmediate memoryDepressive symptomsCognitive dysfunctionHamilton Depression Rating ScaleTreatment of cognitive dysfunctionDepressed response ratesDepression Rating ScaleCognitive enhancing effectsTreating cognitive dysfunctionImprove neurocognitive impairmentsActive rTMS groupDouble-blindSafety of repetitive transcranial magnetic stimulationTranscranial direct current stimulation treatmentMDD inpatientsRepeatable BatterySessions of treatmentEfficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.
Fava M, Stahl S, Pani L, De Martin S, Cutler A, Maletic V, Gorodetzky C, Vocci F, Sapienza F, Kosten T, Kröger C, Champasa P, O'Gorman C, Guidetti C, Alimonti A, Comai S, Mattarei A, Folli F, Bushnell D, Traversa S, Inturrisi C, Manfredi P, Pappagallo M. Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial. The Journal Of Clinical Psychiatry 2024, 85 PMID: 38917366, DOI: 10.4088/jcp.24m15265.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating ScaleIntent-to-treatIntent-to-treat analysisStandard antidepressantsDepressive disorderPost hoc analysisBaseline Montgomery-Asberg Depression Rating ScaleInadequate response to standard antidepressantsSevere depressionPost hoc analysis of patientsDepression Rating ScaleMajor depressive disorderAnalysis of patientsAdverse eventsMontgomery-AsbergConsistent with prior studiesPlacebo-controlled trialRating ScaleEfficacy measuresPer-protocolIntent-to-treat populationTreatment adherencePhase 3 randomized controlled trialsAdjunctive treatmentMDDEnhancing post-traumatic stress disorder patient assessment: leveraging natural language processing for research of domain criteria identification using electronic medical records
Miranda O, Kiehl S, Qi X, Brannock M, Kosten T, Ryan N, Kirisci L, Wang Y, Wang L. Enhancing post-traumatic stress disorder patient assessment: leveraging natural language processing for research of domain criteria identification using electronic medical records. BMC Medical Informatics And Decision Making 2024, 24: 154. PMID: 38835009, PMCID: PMC11151516, DOI: 10.1186/s12911-024-02554-8.Peer-Reviewed Original ResearchConceptsNatural language processingPost-traumatic stress disorderPost-traumatic stress disorder patientsRDoC domainsLanguage processingAbnormal instancesLeverage natural language processingDiagnosis of post-traumatic stress disorderDomain criteriaSimilarity threshold valueF1-macro scorePositive valence systemsHeightened cue reactivityElectronic medical recordsClinical notesF1 scoreCue reactivityStress disorderRDoCValence systemsReal-timeMental health improvementDisease trajectoryExtraction researchSensorimotor disturbancesLetter to the Editor regarding ‘Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone’
Pappagallo M, Kosten T, Gorodetzky C, Vocci F, Sapienza F, De Martin S, Comai S, Mattarei A, Inturrisi C, Manfredi P. Letter to the Editor regarding ‘Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone’. Molecular Psychiatry 2024, 1-3. PMID: 38806691, DOI: 10.1038/s41380-024-02621-6.Peer-Reviewed Original ResearchVaccines as Immunotherapies for Substance Use Disorders
Kosten T. Vaccines as Immunotherapies for Substance Use Disorders. American Journal Of Psychiatry 2024, 181: 362-371. PMID: 38706331, DOI: 10.1176/appi.ajp.20230828.Peer-Reviewed Original ResearchConceptsSubstance use disordersHuman clinical trials of vaccinesPreclinical vaccine studiesClinical trials of vaccinesVaccine clinical trialsHuman clinical trialsTrials of vaccinesVaccine immunotherapyIllicit fentanyl useOpioid pharmacotherapyEffective therapySubstance use disorder treatmentFentanyl useClinical trialsVaccine studiesAnimal modelsAnimal studiesUse disorderVaccine technologyLethal overdoseImmunotherapyVaccineLimited treatment accessFentanyl overdoseTreatment accessEfficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
Yao Y, Guo D, Lu T, Liu F, Huang S, Diao M, Li S, Zhang X, Kosten T, Shi J, Bao Y, Lu L, Han Y. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Research 2024, 335: 115886. PMID: 38574699, DOI: 10.1016/j.psychres.2024.115886.Peer-Reviewed Original ResearchConceptsMental disordersTreatment of mental disordersBorderline personality disorderObsessive-compulsive disorderTreat mood disordersSubstance-use disordersBody dysmorphic disorderPersonality disorderMood disordersDysmorphic disorderNegative moodEating disordersLasting adverse effectsTobacco addictionPsychedelicsDisordersTreat symptomsPsilocybinSleep disordersAyahuascaTherapeutic effectMeta-analyzedLSDPTSDMDMAHighlights and insights from the 34th AAAP Annual Meeting and Scientific Symposium
Kosten T, Domingo C. Highlights and insights from the 34th AAAP Annual Meeting and Scientific Symposium. American Journal On Addictions 2024, 33: 115-116. DOI: 10.1111/ajad.13538.Peer-Reviewed Original ResearchDeep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample
Cinciripini P, Wetter D, Wang J, Yu R, Kypriotakis G, Kumar T, Robinson J, Cui Y, Green C, Bergen A, Kosten T, Scherer S, Shete S. Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample. Scientific Reports 2024, 14: 6385. PMID: 38493193, PMCID: PMC10944542, DOI: 10.1038/s41598-024-56750-7.Peer-Reviewed Original ResearchConceptsIdentification of novel lociSequencing of candidate genesRare variant associationsMapped to genesReceptor signaling pathwayNovel lociGenes associated with regulationVariant associationsCandidate genesProtective lociDeep sequencingRegulation of bodyweightGenetic studiesCanonical pathwaysSignaling pathwayRare variantsGenetic profileTarget of pharmacotherapyTumor suppressionAssociated with cancerGenesPublic health tollRandomized controlled trialsSubstance use disordersEthnically diverse sampleCorrelates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder
Bigdeli T, Barr P, Rajeevan N, Graham D, Li Y, Meyers J, Gorman B, Peterson R, Sayward F, Radhakrishnan K, Natarajan S, Nielsen D, Wilkinson A, Malhotra A, Zhao H, Brophy M, Shi Y, O’Leary T, Gleason T, Przygodzki R, Pyarajan S, Muralidhar S, Gaziano J, Huang G, Concato J, Siever L, DeLisi L, Kimbrel N, Beckham J, Swann A, Kosten T, Fanous A, Aslan M, Harvey P. Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder. Molecular Psychiatry 2024, 29: 2399-2407. PMID: 38491344, DOI: 10.1038/s41380-024-02472-1.Peer-Reviewed Original ResearchBipolar I disorderSuicidal behaviorElectronic health recordsPolygenic scoresVeterans Health AdministrationSelf-reported SBColumbia-Suicide Severity Rating ScaleBipolar I disorder patientsCorrelates of suicidal behaviorClasses of psychotropic medicationsSelf-injurious behaviorHealth recordsSeverity Rating ScaleDiagnosed mental illnessAssociated with clinical variablesElectronic health record codesEHR domainDepressive disorderC-SSRSLifetime diagnosisSubstance-relatedPsychotropic medicationsSuicidal ideationExternalizing behaviorsSuicide attemptsVal/Met BDNF as a genetic risk for a false sense of security in post-discharge suicide risk
Rufino K, Goli P, Patriquin M, Kosten T, Nielsen D, Salas R. Val/Met BDNF as a genetic risk for a false sense of security in post-discharge suicide risk. Journal Of Affective Disorders 2024, 354: 98-103. PMID: 38447916, DOI: 10.1016/j.jad.2024.03.001.Peer-Reviewed Original ResearchSuicide riskAssociated with suicide riskHigher risk of suicide attemptRisk of suicide attemptSuicidal ideation levelsMet variantSuicidal ideation scoresHigh riskPost-discharge suicidesPsychiatric inpatient carePost-discharge periodPsychiatric inpatientsIdeation scoresSuicidal ideationSuicide attemptsInpatient treatmentNo significant associationAssociated with such riskInpatient careDiverse sampleSuicideBDNFIdeational levelGenetic riskInpatientsCorrelates of Risk for Disinhibited Behaviors in the Million Veteran Program Cohort
Barr P, Bigdeli T, Meyers J, Peterson R, Sanchez-Roige S, Mallard T, Dick D, Harden K, Wilkinson A, Graham D, Nielsen D, Swann A, Lipsky R, Kosten T, Aslan M, Harvey P, Kimbrel N, Beckham J, Aslan M, Antonelli M, de Asis M, Bauer M, Brophy M, Concato J, Cunningham F, Freedman R, Gaziano M, Gleason T, Harvey P, Huang G, Kelsoe J, Kosten T, Lehner T, Lohr J, Marder S, Miller P, O Leary T, Patterson T, Peduzzi P, Przygodski R, Siever L, Sklar P, Strakowski S, Zhao H, Fanous A, Farwell W, Malhorta A, Mane S, Palacios P, Bigdeli T, Corsey M, Zaluda L, Johnson J, Sueiro M, Cavaliere D, Jeanpaul V, Maffucci A, Mancini L, Deen J, Muldoon G, Whitbourne S, Canive J, Adamson L, Calais L, Fuldauer G, Kushner R, Toney G, Lackey M, Mank A, Mahdavi N, Villarreal G, Muly E, Amin F, Dent M, Wold J, Fischer B, Elliott A, Felix C, Gill G, Parker P, Logan C, McAlpine J, DeLisi L, Reece S, Hammer M, Agbor-Tabie D, Goodson W, Aslam M, Grainger M, Richtand N, Rybalsky A, Al Jurdi R, Boeckman E, Natividad T, Smith D, Stewart M, Torres S, Zhao Z, Mayeda A, Green A, Hofstetter J, Ngombu S, Scott M, Strasburger A, Sumner J, Paschall G, Mucciarelli J, Owen R, Theus S, Tompkins D, Potkin S, Reist C, Novin M, Khalaghizadeh S, Douyon R, Kumar N, Martinez B, Sponheim S, Bender T, Lucas H, Lyon A, Marggraf M, Sorensen L, Surerus C, Sison C, Amato J, Johnson D, Pagan-Howard N, Adler L, Alerpin S, Leon T, Mattocks K, Araeva N, Sullivan J, Suppes T, Bratcher K, Drag L, Fischer E, Fujitani L, Gill S, Grimm D, Hoblyn J, Nguyen T, Nikolaev E, Shere L, Relova R, Vicencio A, Yip M, Hurford I, Acheampong S, Carfagno G, Haas G, Appelt C, Brown E, Chakraborty B, Kelly E, Klima G, Steinhauer S, Hurley R, Belle R, Eknoyan D, Johnson K, Lamotte J, Granholm E, Bradshaw K, Holden J, Jones R, Le T, Molina I, Peyton M, Ruiz I, Sally L, Tapp A, Devroy S, Jain V, Kilzieh N, Maus L, Miller K, Pope H, Wood A, Meyer E, Givens P, Hicks P, Justice S, McNair K, Pena J, Tharp D, Davis L, Ban M, Cheatum L, Darr P, Grayson W, Munford J, Whitfield B, Wilson E, Melnikoff S, Schwartz B, Tureson M, D Souza D, Forselius K, Ranganathan M, Rispoli L, Sather M, Colling C, Haakenson C, Kruegar D, Muralidhar S, Ramoni R, Breeling J, Chang K, O Donnell C, Tsao P, Moser J, Brewer J, Warren S, Argyres D, Stevens B, Humphries D, Do N, Shayan S, Nguyen X, Pyarajan S, Cho K, Hauser E, Sun Y, Wilson P, McArdle R, Dellitalia L, Harley J, Whittle J. Correlates of Risk for Disinhibited Behaviors in the Million Veteran Program Cohort. JAMA Psychiatry 2024, 81: 188-197. PMID: 37938835, PMCID: PMC10633411, DOI: 10.1001/jamapsychiatry.2023.4141.Peer-Reviewed Original ResearchSubstance use disordersPolygenic risk scoresMillion Veteran ProgramCorrelates of riskElectronic health recordsPsychiatric problemsComorbid psychiatric problemsViral hepatitis C.Chronic airway obstructionHealth recordsElectronic health record dataUS veteran populationMillion Veteran Program cohortCommon etiologic pathwayHealth care centersHealth record dataInternational Statistical ClassificationSuicide-related behaviorsAirway obstructionCohort studyHepatitis C.Recent genome-wide association studiesLiver diseaseUS veteransCare centerDeepBiomarker2: Prediction of Alcohol and Substance Use Disorder Risk in Post-Traumatic Stress Disorder Patients Using Electronic Medical Records and Multiple Social Determinants of Health
Miranda O, Fan P, Qi X, Wang H, Brannock M, Kosten T, Ryan N, Kirisci L, Wang L. DeepBiomarker2: Prediction of Alcohol and Substance Use Disorder Risk in Post-Traumatic Stress Disorder Patients Using Electronic Medical Records and Multiple Social Determinants of Health. Journal Of Personalized Medicine 2024, 14: 94. PMID: 38248795, PMCID: PMC10817272, DOI: 10.3390/jpm14010094.Peer-Reviewed Original ResearchPost-traumatic stress disorderPost-traumatic stress disorder patientsSocial determinants of healthDeterminants of healthMultiple social determinants of healthSubstance use disorder riskSubstance use disordersMultiple social determinantsPredictive of alcoholMedical CenterElectronic medical recordsStress disorderDisorder patientsAverage C-statisticSDoH informationMental disordersSocial determinantsHigh-risk eventsDisorder riskASUDUniversity of Pittsburgh Medical CenterIndicator of increased riskEMR dataZip codesMedication usePrediction of adverse events risk in patients with comorbid post-traumatic stress disorder and alcohol use disorder using electronic medical records by deep learning models
Miranda O, Fan P, Qi X, Wang H, Brannock M, Kosten T, Ryan N, Kirisci L, Wang L. Prediction of adverse events risk in patients with comorbid post-traumatic stress disorder and alcohol use disorder using electronic medical records by deep learning models. Drug And Alcohol Dependence 2024, 255: 111066. PMID: 38217979, PMCID: PMC10853953, DOI: 10.1016/j.drugalcdep.2023.111066.Peer-Reviewed Original ResearchConceptsPost-traumatic stress disorderAlcohol use disorderComorbid post-traumatic stress disorderStress disorderUse disorderCognitive behavioral therapyElectronic medical recordsBehavioral therapyMental disordersNeighborhood-level social determinants of healthNeighborhood-level social determinantsSocial determinants of healthArea under the receiver operating curveDeterminants of healthVeteran dataMedical recordsDisordersPsychotherapyPrediction of adverse eventsVeteran statusPatient's increased riskHigh-risk populationAnalyzed electronic medical recordsUniversity of Pittsburgh Medical CenterAdverse eventsGinkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial
Wang D, Tian Y, Chen J, Zhu R, Li J, Zhou H, Chen D, Wang L, Kosten T, Zhang X. Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial. Current Neuropharmacology 2024, 22: 2443-2452. PMID: 38919004, PMCID: PMC11451319, DOI: 10.2174/1570159x22666240530095721.Peer-Reviewed Original ResearchAbnormal Involuntary Movement ScaleMnSOD Ala-9Val polymorphismTardive dyskinesiaTD patientsTD symptomsAla-9Val polymorphismPathophysiology of tardive dyskinesiaNon-TDHealthy controlsNon-TD patientsSeverity of TDMovement ScaleAla alleleDouble-blind clinical trialIncreased MnSOD activityMnSOD activityWeeks of treatmentVal/Val genotypeTreatment responseDyskinesiaGinkgo biloba extractEGb761 groupManganese superoxide dismutaseSymptomsClinical trials
2023
A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naïve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms
Wang D, Chen D, Xiu M, Wang L, Kosten T, Zhang X. A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naïve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacology 2023, 49: 893-902. PMID: 37903861, PMCID: PMC10948781, DOI: 10.1038/s41386-023-01760-8.Peer-Reviewed Original ResearchFirst-episode SCZ patientsClinical symptomsSCZ patientsCOX2 inhibitorsCyclooxygenase-2Drug-naïve first-episode schizophreniaCognitive impairmentCentral nervous system inflammationNervous system inflammationPlacebo-controlled trialSubscale scoresPANSS total scoreFirst-episode schizophreniaEffect of celecoxibCase-control studyPathogenesis of schizophreniaNegative Syndrome ScaleArachidonic acid pathwayCOX-2 geneCelecoxib 400Pharmacogenetic impactRs5275 polymorphismPlacebo groupSystem inflammationPANSS totalDisorders Due to Substance Use: General Approaches
Kosten T, Domingo C. Disorders Due to Substance Use: General Approaches. 2023, 1-16. DOI: 10.1007/978-3-030-42825-9_92-1.Peer-Reviewed Original ResearchSubstance use disordersDSM-5ICD-11Depressive symptomsSubstance use disorder criteriaBorderline personality disorderSubstance-induced conditionsGoal of abstinenceDrug withdrawal symptomsPersonality disorderDepressive disorderAgonist maintenanceWithdrawal symptomsAcute detoxificationLifetime substanceSUD diagnosisAbused drugsDevelopmental differencesUrine toxicologySubstance useAlcohol usePsychosocial rehabilitationDisordersDrug useSymptoms